# Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Source: https://onco.cc/trials/nct05845450/  
OnCo record `nct05845450` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trastuzumab deruxtecan, durvalumab, panitumumab, botensilimab and other drugs in colorectal cancer, run by Gruppo Oncologico del Nord-Ovest, now recruiting.

## Summary

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) is a phase 2, interventional study registered as NCT05845450 by Gruppo Oncologico del Nord-Ovest, with a registry enrolment figure of 197 participants, started 2023-05-11 and due to reach its primary completion in 2027-05. Interventions recorded: Trastuzumab deruxtecan; Durvalumab; Panitumumab; Botensilimab; Balstilimab; Sotorasib; Vorbipiprant; Nivolumab; Amivantamab; Botensilimab; Balstilimab. Conditions listed: Colorectal Cancer; Resectable Colorectal Carcinoma. Primary outcome: major pathological response rate. Colorectal eligibility wording from the registry: "* Histologically confirmed colorectal cancer adenocarcinoma that is judged as initially resectable with elective surgery aimed at radical intent with R0 margins as per multidisciplinary team assessment". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05845450
- Phase: 2
- Setting: Window-of-opportunity Umbrella Platform Trial of Short-course Pre-operative Targeted Treatments in Patients With Molecularly Selected and Resectable Primary Colorectal Cancer: the UNICORN Study
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Enrolled: 197

## Sources

- ClinicalTrials.gov NCT05845450: https://clinicaltrials.gov/study/NCT05845450

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Balstilimab](https://onco.cc/drugs/balstilimab/), [Botensilimab](https://onco.cc/drugs/botensilimab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Panitumumab](https://onco.cc/drugs/panitumumab/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05845450.json